Gabriel Levitt, President of Prescription Justice submitted comments to the Food and Drug Administration (FDA) in response to the Notice of Proposed Rulemaking (NPRM) titled "Importation of Prescription Drugs, FDA-2019-N-5711, 84 Fed. Reg. 70796.
Today, Prescription Justice announced that it has published a Congressional report card on drug prices. This first of its kind Congressional report card on drug prices can help voters and political organizations determine who they want to support in upcoming elections.
Today, Prescription Justice issued a press release announcing new data showing that 45 million Americans did not fill a prescription in 2016 because of drug costs and the publication of its policy report recommending that President Donald Trump take executive actions to help consumers more easily import lower cost medications for personal use. Previously, Prescription Justice reported that 35 million American adults did not fill a prescription because of cost. The new data, extracted from the Commonwealth Fund’s 2016 International Health Policy Survey of Adults, shows the crisis of high drug prices to be worse than is widely reported.
We are proud to announce that we have changed our organization’s (DBA) name from Prescription Justice Action Group to Prescription Justice, which is a simpler expression of our core position: making prescription drugs affordable is an issue of justice for Americans and we will help them obtain it.
Last year, U.S. spending on prescription drugs was at a record breaking $425 billion before discounts, and is expected to rise by 22% annually over the next five years, which is 400%, or over $600 billion by 2020. As Donald Trump is sworn in as the 45th president of the United States, Americans across the country concerned with the soaring costs of prescription medications, will be looking to President Trump and Congress for solutions to address this national crisis.
President-Elect Trump’s top priority for healthcare reform is to repeal the Affordable Care Act, but most Americans are more concerned about prescription drug prices than Obamacare.